Deep Genomics vs Illumina
Side-by-side comparison of AI visibility scores, market position, and capabilities
Deep Genomics uses AI to discover and design RNA-based therapies for genetic diseases; its AI Workbench platform decodes RNA biology at scale; raised over $180M in funding including a $40M Series C extension in 2022;
About
Deep Genomics is a biopharmaceutical company founded in 2015 by Brendan Frey and headquartered in Toronto, Ontario, Canada. The company applies artificial intelligence to the challenge of RNA biology — developing a proprietary AI Workbench platform that can predict how genetic variants affect RNA splicing, processing, and gene expression. This computational capability allows Deep Genomics to identify disease-causing mutations that alter RNA function and to design antisense oligonucleotide (ASO) and other RNA-based therapies that correct those molecular defects — a process that traditionally requires years of manual biological experimentation.
World's dominant DNA sequencing platform with ~80% market share; ~$4.34B FY2025 revenue. Powers clinical genomics, oncology diagnostics, and population-scale sequencing.
About
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applications. The company's sequencing-by-synthesis (SBS) chemistry and NovaSeq, NextSeq, and MiSeq instrument platforms have become the standard infrastructure for genomic research, clinical oncology, reproductive health, and infectious disease diagnostics worldwide.\n\nIllumina's business model combines high-margin consumable sales (flow cells, reagent kits) with instrument placements, creating a razor-and-blades recurring revenue structure. Its clinical sequencing segment showed accelerating growth in 2025, with clinical consumables revenue up 20% year-over-year in Q4. The company is expanding into spatial transcriptomics and multi-omics with new instruments unveiled at AGBT 2025, broadening its addressable market.\n\nIllumina reported $4.34 billion in FY2025 revenue and guides to $4.5–$4.6 billion for FY2026, with non-GAAP operating margins of ~23%. Having divested Grail (its liquid biopsy subsidiary) following regulatory pressure, Illumina is refocused on its core sequencing franchise and positioned to benefit from continued clinical adoption of genomic medicine.
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.